

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

Name	Commercial Interest:Relationship
Anne-Christine Bay-Jensen	Nordic Bioscience:Employee - Session will not receive credit
	Wolters Kluwer:Consultant
Kim Bennell	National Health & Medical Research Council, Australian Research Council, Medibank Private:Research Grant Overall Principal Investigator
Philip Conaghan	Eli Lilly, Flexion, Galapagos, Novartis, Pfizer, EMD Serono:Consultant
Yves Henrotin	Artialis SA:Scientific/Medical Advisory Board Member
Stefan Lohmander	Honorarium received:Consultant Honorarium received:Scientific/Medical Advisory Board Member
	Vizuri:Scientific/Medical Advisory Board Member
Anne-Marie Malfait	Eli Lilly, Pfizer, AKP, Ceva:Consultant Galapagos, GSK:Research Grant Overall Principal Investigator
Frank Roemer	Boston Imaging Core Lab. (BICL), LLC:Stock Shareholder Calibr - California Institute of Biomedical Research:Consultant